European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies

Description du projet

Des biomarqueurs pour la stéatose hépatique non alcoolique

La stéatose hépatique non alcoolique (NAFLD pour «non-alcoholic fatty liver disease») est une maladie complexe associée à une accumulation de graisse et à une inflammation du foie. La NAFLD est difficile à diagnostiquer et à traiter car les mécanismes moléculaires sous-jacents sont toujours incompris. Le projet halt-RONIN, financé par l’UE, entend étudier la manière dont les patients en bonne santé développent la NAFLD. Le consortium mettra au point des modèles in vitro et in vivo et, parallèlement aux données cliniques des patients, il découvrira de nouveaux biomarqueurs et des cibles moléculaires spécifiques. Les résultats devraient contribuer au diagnostic de la NAFLD, au développement d’interventions visant à modifier la maladie ainsi qu’à l’élaboration de lignes directrices en matière de prévention.

Objectif

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial chronic inflammatory disease that is prevalent in 1 of 4 individuals with a significant personal, socioeconomic and healthcare burden, especially at the later, more severe inflammatory stage of disease - non-alcoholic steatohepatitis (NASH). Despite the severe negative impact of the disease on society, NAFLD remains difficult to diagnose and treat. Additionally, the molecular mechanisms underlying the transition from health to fatty liver to NASH remain poorly understood due to the lack of models that faithfully reflect the complexity of human disease. Hence, Halt-RONIN aims to uncover the early triggers of disease initiation and complex mechanistic drivers of disease progression by implementing a systems biology approach with integrative disease modelling resulting in opportunities for the improvement of the existing detection methods, providing a blueprint to inform personalized intervention strategies and drug discovery for NAFLD. To achieve this goal, Halt-RONIN will combine experimental data from advanced in vitro and in vivo models with multimodal data from extensive human NAFLD cohorts and biobanks and use in silico machine learning approaches, to discover new biomarkers and molecular targets specific to each stage of the health-to-disease transition. By validating preclinical experimental findings with real-world data, RONIN will allow for the discovery of novel biomarkers and molecular targets that are specific to the individual patient’s pathology. Consequently, healthcare professionals will gain the tools and knowledge required to diagnose and establish guidelines for the prevention and treatment of inflammation-driven health to disease. As such, in the long-term RONIN will decrease the number of NAFL patients who progress into NASH and provide disease-modifying strategies to improve patient outcomes.

Coordinateur

UNIVERSIDAD COMPLUTENSE DE MADRID
Contribution nette de l'UE
€ 815 651,53
Adresse
AVENIDA DE SENECA 2
28040 Madrid
Espagne

Voir sur la carte

Région
Comunidad de Madrid Comunidad de Madrid Madrid
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 815 651,53

Participants (19)

Partenaires (3)